SCHEMBL10127744

SCHEMBL10127744

Cc1ccc(N)cc1C1CCN(C2CCN(C)CC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 2/20 0.52
HTR1B P28222 2/20 0.52
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR1F P30939 2/20 0.39
ALOX15 P16050 1/20 0.39
TLR9 Q9NR96 2/20 0.38
TLR7 Q9NYK1 2/20 0.38
CYP3A4 P08684 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
THPO P40225 1/20 0.37
DRD1 P21728 1/20 0.36
ALDH1A1 P00352 1/20 0.36
L3MBTL3 Q96JM7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10127647 0.89 HTR1D (0.52) HTR1DHTR1BGAASMN1; SMN2HTR1F
SCHEMBL328237 0.82 HTR1D (0.49) HTR1DHTR1BHTR1FTLR9TLR7
SCHEMBL10036174 0.82 HTR1D (0.51) HTR1DHTR1BGAASMN1; SMN2HTR1F
SCHEMBL10036163 0.80 HTR1D (0.49) HTR1DHTR1BHTR1FTLR9TLR7
SCHEMBL13723802 0.79 HTR1D (0.43) HTR1DHTR1BGAAALOX15CYP3A4
SCHEMBL522141 0.79 HTR1D (0.56) HTR1DHTR1BGAASMN1; SMN2HTR1F
SCHEMBL18031194 0.78 ALDH1A1 (0.50) HTR1DHTR1BGAASMN1; SMN2ALOX15
SCHEMBL328439 0.77 SLC18A3 (0.53) HTR1DHTR1BGAASMN1; SMN2TLR9
SCHEMBL14876247 0.77 HTR1D (0.57) HTR1DHTR1BGAASMN1; SMN2HTR1F
SCHEMBL34463602 0.77 HTR1D (0.57) HTR1DHTR1BGAASMN1; SMN2HTR1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 HTR1D 3635/4885HTR1B 3677/4885GAA 3821/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 HTR1D 3635/4885HTR1B 3677/4885GAA 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.